GlassScriptPhysician profile
Abdullah Mohammed Alam
NPI 1083292858
$2,220.69
in general payments reported to CMS, 2019-2025
19 companies · $585 in 2025
The $585 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.48 · 2022: $282 · 2023: $519 · 2024: $818 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $365.51 | 2023-2025 | Briviact, Rystiggo |
| Alexion Pharmaceuticals, INC. | $356.35 | 2023-2025 | Ultomiris |
| Emd Serono, INC. | $283.79 | 2022-2025 | Mavenclad |
| Astrazeneca Pharmaceuticals LP | $194.02 | 2024-2025 | Wainua, Andexxa |
| Jazz Pharmaceuticals INC. | $149.90 | 2023-2024 | Epidiolex |
| Novartis Pharmaceuticals Corporation | $127.10 | 2024 | |
| Abbvie INC. | $119.31 | 2023-2024 | Botox |
| Lilly USA, LLC | $113.60 | 2024-2025 | Amyvid, Kisunla, Reyvow |
| E.R. Squibb & Sons, L.L.C. | $108.80 | 2022 | |
| Genentech USA, INC. | $100.30 | 2022-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Takeda Pharmaceuticals U.S.A., INC. | $70.78 | 2022-2024 | Hyqvia |
| Tg Therapeutics, INC. | $51.72 | 2025 | |
| Sk Life Science, INC. | $34.28 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.92 | 2022 | |
| Averitas Pharma INC. | $27.10 | 2023 | Qutenza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $23.43 | 2024 | Impella |
| Biogen, INC. | $17.37 | 2022 | |
| Horizon Therapeutics Plc | $15.90 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.03 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.